Safety, Antiviral Effect and PK of BI 207127 + BI 201335 +/- RBV for 4 up to 40 Weeks in Patients With Chronic HCV Genotype 1 Infection

NCT01132313 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

488

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: BI 207127
DRUG: BI 201335
DRUG: BI 207127
DRUG: BI 201335
DRUG: Ribavirin
DRUG: Ribavirin
DRUG: Ribavirin
DRUG: BI 207127
DRUG: BI 207127
DRUG: BI 207127
DRUG: BI 201335
DRUG: Ribavirin
DRUG: Ribavirin
DRUG: BI 207127
DRUG: BI 207127
DRUG: BI 201335
DRUG: BI 201335
DRUG: Ribavirin
DRUG: BI 201335
DRUG: BI 201335

Sponsor

Boehringer Ingelheim